Taxotere and JMR-132
 

http://news.yahoo.com/s/afp/20070130...ushealthcancer

Combination therapy promising for breast cancer: Study

CHICAGO (AFP) - An experimental new treatment for breast cancer can dramatically shrink, and in some cases, eliminate, tumors in mice that have been infected with the disease, a study has said. <SCRIPT language=javascript>if(window.yzq_d==null)window.y zq_d=new Object();window.yzq_d['ipGHBdGDJHQ-']='&U=13b5fr6u1%2fN%3dipGHBdGDJHQ-%2fC%3d571699.10029817.10887929.1442997%2fD%3dLREC %2fB%3d4368327';</SCRIPT><NOSCRIPT>http://us.bc.yahoo.com/b?P=p_QCx0WTV...%2fB%3d4368327</NOSCRIPT>
The new therapy involves a combination of a chemotherapy drug, Taxotere (generic name: docetaxel) and a novel compound called JMR-132, that starves the tumor of growth-stimulating hormone. The compound binds to receptors on the tumor, and in so doing blocks the release of the growth hormone.

Tested separately, the drug and the growth factor inhibitor were extremely effective at shrinking the tumors in mice infected with a hard-to-treat, estrogen-independent form of breast cancer.

On its own, the Taxotere reduced the volume of the mice tumors by an average of 74 percent in three weeks. In mice treated with JMR-132, the volume reduction was 63 percent.

Together, the two therapies reduced the volume of the cancerous cells by more than 97 percent. In some cases, when the researchers examined the dead mice, they could not find any cancer cells at all.

What's more, the treatment did not appear to be toxic or trigger any other major side effects in the animals, suggesting it might be well-tolerated in humans, the researchers said.

Thanks Eric for this post which covers the new JMR-132 drug. It is likely to be developed past mice experiments since "Tulane University has applied for a patent on the GHRH antagonist JMR-132" . This makes it attractive to potential licencees among pharmaceutical companies.

I am not sure about the stated inocuity of the Docetaxel dosage since in mice experiments they used it intraperitonally while in humans it is given as an I.V.
I don't know how to correlate the dose of 20mg/kg in mice with the 75 to 100mg per square meter in humans.
However the 10 µg/day (sub cutanous) looks very small & hopefully less toxic in humans than Docetaxel.